Nitya Krishnan1, Timothy McAlindon2, Melynn Nuite, Kimberly Carr, Deborah Burstein1,3, Lori Lyn Price, Klaus Flechsenhar4
1Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States; 2Division of Rheumatology, Tufts Medical Center, Boston, MA, United States; 3Health Sciences and Technology , Harvard Medical School, Boston, MA, United States; 4Research & Development, Gelita AG, Eberbach, Germany
A pilot study was performed to determine if dGEMRIC or T2-mapping could detect changes in knee cartilage among participants treated with collagen hydrolysate (Fortigel) versus placebo. A randomized, double-blind, 24-week clinical trial included 30 participants with symptomatic knee OA. Half received 10 grams collagen hydrolysate orally. The dGEMRIC index was able to discriminate between treatment and placebo groups in the tibial regions with an increase in dGEMRIC in the active arm. The sample size was small, and so these data are preliminary.